knowledge -WSS

knowledge

author：hotspot 2025-10-01 18:34:34 - browse：6273

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The blockbuster weight loss and diabetes drug sold by Eli Lilly also appears to improve fatty liver disease, according to early clinical trial data the pharmaceutical company released Tuesday.

Eli Lilly reported during its fourth-quarter earnings call that tirzepatide, which is sold commercially as Mounjaro or Zepbound, succeeded in a Phase 2 test as a treatment for the liver disease MASH. Around 74% of adults in the trial taking the drug were free of MASH after 52 weeks, compared to approximately 13% of the placebo group.

MASH, formerly known as NASH, is a liver disease characterized by excess fat and inflammation. The chronic inflammation can also lead to liver scarring, or fibrosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Readout Newsletter: Beam, Prozac, "TechBio" and more

focus

WSS

Medicare isn't yet testing food as medicine

NEJM study measures Covid brain fog, impact on IQ

5 ways to address the shortage of health care workers

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

CDC advisory group OKs chikungunya vaccine

David Sabatini, ex

explore

knowledge

entertainment

George Santos makes 1st court appearance after pleading not guilty to 13 counts

'Vaccine

Walensky prepares to leave CDC — and Congress — behind

Cholera vaccine supplies dangerously low, outbreaks surging

Alkermes shareholders re

Color Health wants to make cancer screenings convenient

Guidelines to prevent youth baseball injuries need more muscle

Pfizer is about to make a big push in cancer. Will investors listen?

Medicare proposal to cover medical devices draws a mixed reaction

Using force crossed my mind when examining a defiant young patient

hotspot

NEJM study measures Covid brain fog, impact on IQ

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Elisabeth Bik tackles the widespread issue of research misconduct

5 ways to address the shortage of health care workers

Virtual repurposing can help discover new uses for existing drugs

Children’s Hospital revives plan for pedestrian bridge

explore

focus

focus

entertainment